Navigation Links
Takeda Responds to U.S. Food and Drug Administration Update to Safety Review of ACTOS (pioglitazone HCl)
Date:6/15/2011

DEERFIELD, Ill., June 15, 2011 /PRNewswire/ -- Following an announcement today from the U.S. Food and Drug Administration (FDA) regarding an update to its safety review of ACTOS, Takeda Pharmaceuticals North America, Inc. (Takeda) is confident in the therapeutic benefits of ACTOS and its importance as a treatment for type 2 diabetes. The company remains committed to ACTOS and ACTOS-containing medications, and to the millions of people living with the disease.

Takeda is dedicated to patient safety, and to ensuring that patients and physicians have accurate information regarding ACTOS. Takeda is committed to ongoing clinical research to understand and investigate potential safety concerns, and, working with appropriate regulatory agencies, is currently supporting a ten-year epidemiological study, started in 2002 by the University of Pennsylvania (U. of Penn.) and Kaiser Permanente Diabetes Registry, Northern California (KPNC), investigating the questions raised about ACTOS and bladder cancer. Takeda has been working with the FDA and European Medicines Agency (EMA) and has provided them with interim data from this study on a regular basis. Takeda is committed to supporting this study through its conclusion at the end of 2012 and will report on the final results upon completion.  

In the interim analysis of this epidemiologic data, published in Diabetes Care April 2011, the primary endpoint showed that treatment with ACTOS was not associated with a statistically significant increase in the incidence of bladder cancer. The investigators reported that "short-term use of pioglitazone was not associated with an increased incidence of bladder cancer, but use for more than two years was weakly associated with increased risk."  

Based on its recent data review, FDA has informed the public that "...use of the diabetes medication ACTOS (pioglitazone) for more than one year may be associated with an increased risk of bladder cancer." 
'/>"/>

SOURCE Takeda Pharmaceuticals North America, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Takeda to Acquire Nycomed
2. Amylin and Takeda Voluntarily Suspend Clinical Activities in Obesity Trial
3. Intra-Cellular Therapies and Takeda Enter into Worldwide Collaboration to Develop and Commercialize Compounds for Schizophrenia
4. Handa Pharmaceuticals Announces Submission of Its First-to-File ANDA for Takedas DEXILANT®
5. Takeda Submits New Drug Application in the U.S. for Azilsartan Medoxomil Plus Chlorthalidone, an Investigational Fixed-Dose Combination for the Treatment of Hypertension
6. Takeda Enters Into Global Strategic Partnerships With Covance and Quintiles
7. Takeda Completes Settlements With All Defendants in U.S. Patent Litigation Involving ACTOS® (pioglitazone HCI), ACTOplus met® (pioglitazone HCl and metformin HCl) and duetact® (pioglitazone HCl and glimepiride)
8. Takeda Responds to Announcement about Suspension of Rosiglitazone Marketing Authorization in Europe and Restrictions in the U.S.
9. Arthritis Foundation and Takeda Launch First-Ever National Gout Public Service Announcement (PSA) Campaign, Urging People Living With Gout to Keep Enjoying Lifes Simple Pleasures
10. Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in North America
11. Takeda Responds to FDA Advisory Committee Recommendation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... Oct. 1, 2014 Trovagene, Inc., (NASDAQ: ... today that Eli Diamond , MD, Assistant ... (MSK), presented clinical data from an ongoing study ... platform for the determination of oncogene mutational status ... The results were presented to both treating physicians ...
(Date:10/1/2014)... , Oct. 1, 2014   Cypher Genomics, Inc., ... of J. Patrick Ravenel as chief technology ... software and systems experience and a proven track record ... "Patrick has been recognized as a ... systems and is known industry-wide for delivering innovative products ...
(Date:10/1/2014)... 1, 2014 Quantum Materials Corp (OTCQB:QTMM) ... of photoactive quantum dots for use in ... numerous advantages for solar power generation, the high ... quantum dots with which to develop thin film ... commercial utilization and acceptance. The company is also ...
Breaking Medicine Technology:Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 2Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 3Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 4Cypher Genomics Appoints J. Patrick Ravenel Chief Technology Officer 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 3
... growing appetite for health and wellness devices, and this represents ... been tapped, according to a study from IBM (NYSE: ... wellness device innovations of the future, which have the potential ... healthcare provider over the next five years. (Photo: ...
... 2011 Providers of durable medical equipment and services (DME) ... repeal Medicare,s controversial "competitive" bidding for homecare, which cuts quality ... The program is opposed by the ... advocacy groups such as the ALS Association and ...
Cached Medicine Technology:IBM Study Identifies New Generation of Connected Health Devices 2IBM Study Identifies New Generation of Connected Health Devices 3IBM Study Identifies New Generation of Connected Health Devices 4IBM Study Identifies New Generation of Connected Health Devices 5At-Home Care Businesses Urge President Obama to Repeal Medicare Program that Cuts Access to Homecare 2At-Home Care Businesses Urge President Obama to Repeal Medicare Program that Cuts Access to Homecare 3At-Home Care Businesses Urge President Obama to Repeal Medicare Program that Cuts Access to Homecare 4
(Date:10/1/2014)... First Warning Systems, a pioneer in ... throughout the body, announced the company is changing its ... company’s breadth of upcoming product releases. The initial focus ... , “Our initial focus will be an ‘Internet of ... circadian cellular changes over time,” said Rob Royea, president ...
(Date:10/1/2014)... new genetic finding from Duke Medicine suggests that some ... might also be hard-wired to gain weight when exposed ... , An estimated 13 percent of people, all of ... knowing this could help them reduce heart disease with ... stress management. , "Genetic susceptibility, psychosocial stress and metabolic ...
(Date:10/1/2014)... NoteSwift Inc., announced today their new NoteSwift™ 2.0 ... NoteSwift is the bridge between the EHR and Dragon ... clinical information at the point of care. NoteSwift reduces ... by more than half – and virtually eliminates mouse ... state impedes EHR use according to the June 12, ...
(Date:10/1/2014)... 01, 2014 Nordic Naturals is ... very special cause. The campaign—“Buy One Bottle. Help ... for Veterans, a nonprofit organization that helps rebuild ... shelter dogs that would otherwise face euthanasia. From ... will support monthly donations of Nordic Naturals omega-3s ...
(Date:10/1/2014)... October 01, 2014 Two bicyclists began ... them across the country in an effort to raise ... families. The cyclists, a father-daughter team, plan to ... in Blaine, Washington and finishing in Key West Florida. ... For The Warriors®, a national nonprofit organization that assists ...
Breaking Medicine News(10 mins):Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 3Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 4Health News:Gene interacts with stress and leads to heart disease in some people 2Health News:NoteSwift Joins Allscripts Developer Program 2Health News:NoteSwift Joins Allscripts Developer Program 3Health News:Nordic Naturals® Inspires Support for Paws for Veterans -- ‘Buy One Bottle. Help Two Heroes.’ Initiative Kicks Off October 1 2Health News:Father-Daughter Cycling Duo to Ride Cross-Country to Benefit Hope For The Warriors 2
... hope to detect the disease while it is still ... scientists say they have found small molecules in the ... could have diagnostic implications in the future. , Levels ... suffering from pancreatic cancer, the fourth-leading cancer killer in ...
... harsh skin toxicity associated with a widely used cancer drug, ... Cancer Biology and Therapy by researchers from City of ... (Erbitux) is a monoclonal antibody that binds to and inhibits ... to treat colorectal cancer and head and neck cancer. Although ...
... combined with a defibrillator (CRT-D) implanted had a 34 ... failure when compared to patients receiving only an implanted ... online today in the New England Journal of ... of Cardiology Congress (ESC) in Barcelona, Spain. The overall ...
... is available in French . , ... serious autoimmune disorders which cause muscular inflammation are at ... of Montreal researchers. Dr. Christian A. Pineau and his ... Health Centre (RI-MUHC) have linked muscular inflammation to increased ...
... , , , , ... in grants for four Northwest nonprofits: HealthMatters of Central Oregon ... Northwest Organization of Nurse Executives . The grants all ... increase access to care. , , "At The Regence ...
... , PITTSBURGH, Sept. 1 On Friday, September 18, ... former president of the renowned public relations agency Porter Novelli, former ... native William (Bill) D. Novelli. Enjoy lunch and a presentation ... to accomplish this, and what it means for seniors in the ...
Cached Medicine News:Health News:Blood Test May Spot Pancreatic Cancer Early 2Health News:Prodrug could help curb skin toxicity related to EGFR-inhibiting cancer drugs 2Health News:Stuy in NEJM: New therapy prevents heart failure 2Health News:Researchers link inflammatory diseases to increased cardiovascular risk 2Health News:Regence Foundation Awards Nearly $250,000 in Grants to Northwest Nonprofits 2
... Hand Instruments were developed in surgeon's desire ... still having an instrument with the strength ... fear of the bending or breaking. Arthrotek ... to conform to the surgeon's hand. This ...
The narrow shaft and compact jaw design facilitates access and use in tight spaces, particularly useful in the posterior aspect of the knee....
... Hand Instruments were developed in surgeon's desire ... still having an instrument with the strength ... fear of the bending or breaking. Arthrotek ... to conform to the surgeon's hand. This ...
... Instruments were developed in surgeon's desire to ... having an instrument with the strength to ... of the bending or breaking. Arthrotek Hand ... conform to the surgeon's hand. This new ...
Medicine Products: